BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 41 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,087,408 | -1.6% | 1,120,000 | 0.0% | 0.02% | 0.0% |
| Q2 2023 | $1,104,578 | -4.0% | 1,120,000 | 0.0% | 0.02% | -15.4% |
| Q1 2023 | $1,150,498 | -83.4% | 1,120,000 | -83.5% | 0.03% | -86.9% |
| Q2 2018 | $6,913,000 | +8.1% | 6,800,000 | 0.0% | 0.20% | +6.5% |
| Q1 2018 | $6,395,000 | -5.9% | 6,800,000 | 0.0% | 0.19% | -4.6% |
| Q4 2017 | $6,794,000 | -14.3% | 6,800,000 | -12.8% | 0.20% | -13.7% |
| Q3 2017 | $7,924,000 | – | 7,800,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |